Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial...
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
MENLO PARK, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.98 | -8.5677196019 | 23.11 | 23.57 | 19.8375 | 937234 | 20.86694084 | CS |
| 4 | 1.76 | 9.08621579763 | 19.37 | 25.65 | 18.2 | 392112 | 21.35297156 | CS |
| 12 | -3.63 | -14.6607431341 | 24.76 | 31.13 | 18.2 | 222629 | 23.1048301 | CS |
| 26 | -4.37 | -17.137254902 | 25.5 | 31.13 | 18.2 | 181673 | 23.24747078 | CS |
| 52 | -4.37 | -17.137254902 | 25.5 | 31.13 | 18.2 | 181673 | 23.24747078 | CS |
| 156 | -4.37 | -17.137254902 | 25.5 | 31.13 | 18.2 | 181673 | 23.24747078 | CS |
| 260 | -4.37 | -17.137254902 | 25.5 | 31.13 | 18.2 | 181673 | 23.24747078 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
